MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
6300 Zug
Switzerland
VIA EDGAR
September 7, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: MoonLake Immunotherapeutics
Registration Statement on Form S-3 (File No. 333-274286)
To Whom it May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), MoonLake Immunotherapeutics (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 11, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden C. Berns at (415) 393-4631.
| | | | | |
| Sincerely, | |
| |
| MoonLake Immunotherapeutics | |
| |
| /s/ Matthias Bodenstedt | |
| Matthias Bodenstedt | |
| Chief Financial Officer | |
| | | | | |
| cc: | Ryan A. Murr, Gibson, Dunn & Crutcher LLP |
| Branden C. Berns, Gibson, Dunn & Crutcher LLP |
